Hookipa Pharma’s (HOOK) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $6.50 price objective on the stock. HC Wainwright also issued estimates for Hookipa Pharma’s Q1 2024 earnings at ($0.18) EPS, Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at $0.31 EPS.

Separately, Royal Bank of Canada reduced their price target on shares of Hookipa Pharma from $6.00 to $5.00 and set an outperform rating for the company in a research report on Tuesday, January 30th.

Hookipa Pharma Trading Down 1.2 %

NASDAQ HOOK opened at $0.71 on Monday. The company has a fifty day simple moving average of $0.70 and a 200 day simple moving average of $0.63. Hookipa Pharma has a 12-month low of $0.41 and a 12-month high of $2.05. The company has a market cap of $59.77 million, a P/E ratio of -0.81 and a beta of 1.03.

Hedge Funds Weigh In On Hookipa Pharma

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Hookipa Pharma during the 4th quarter worth $43,000. Virtu Financial LLC purchased a new position in Hookipa Pharma during the 2nd quarter worth $47,000. Two Sigma Investments LP purchased a new position in Hookipa Pharma during the 3rd quarter worth $51,000. Mirabella Financial Services LLP purchased a new position in Hookipa Pharma during the 1st quarter worth $82,000. Finally, Alyeska Investment Group L.P. purchased a new position in Hookipa Pharma during the 4th quarter worth $103,000. 63.88% of the stock is owned by hedge funds and other institutional investors.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.